Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company concealed material adverse facts regarding its clinical performance and misrepresented the efficacy of its product SLK compared to competitors [2][3]. Legal Allegations - The lawsuit focuses on the alleged discrepancy between MoonLake's public statements and the actual clinical data from the Phase 3 VELA trials [3]. - It is claimed that MoonLake did not disclose that SLK shares the same molecular targets as BIMZELX, a competitor, which could mislead investors about SLK's competitive positioning [3]. - The company allegedly misrepresented that the Nanobody structure would lead to superior clinical efficacy, which was not supported by the trial results [3]. Financial Impact - MoonLake's stock price plummeted from $61.99 to $6.24, representing a 90% loss on September 29, 2025, following the disclosure of the alleged trial flaws [3]. - Investors who purchased shares during the Class Period (March 10, 2024, through September 29, 2025) and suffered losses are encouraged to contact the law firm for potential legal action [4]. Next Steps for Investors - The deadline for investors to move the Court for appointment as lead plaintiff is December 15, 2025 [1][5]. - Hagens Berman has a history of securing over $2.9 billion in settlements for investors, indicating a strong track record in similar cases [4][7].